RxDoctor Payments Data

Karen Hunter, MD

Internal Medicine · Greer, SCNPI 1023086147

Payments from drug & device makers

$5,535in general payments, 2019–2025

Across 339 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$916
  • AbbVie$516
  • Lilly USA, LLC$388
  • Novartis$366
  • Abbott$334
  • Sanofi-aventis U.S. LLC$240
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$5,535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,535 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$240,289
Medicare patients
490
Services billed
4,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$126,627
MounjaroTirzepatide106$110,109
JardianceEmpagliflozin106$102,905
OzempicSemaglutide63$76,920
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog44$70,089
XareltoRivaroxaban58$65,481
MyrbetriqMirabegron45$34,586
TrulicityDulaglutide31$33,743
Breo ElliptaFluticasone/Vilanterol60$25,633
FarxigaDapagliflozin Propanediol14$17,746
JanuviaSitagliptin Phosphate16$17,201
Lantus SolostarInsulin Glargine,hum.Rec.Anlog104$16,552
BrilintaTicagrelor18$12,756
KerendiaFinerenone11$11,161
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$388$143,851137 claims
PfizerEliquis$67$126,627141 claims
Boehringer IngelheimJardiance$83$102,905106 claims
Novo NordiskOzempic$916$76,92063 claims
Johnson & JohnsonXarelto$199$65,48158 claims
Astellas Pharma US IncMyrbetriq$173$34,58645 claims
AstraZenecaFarxiga, Brilinta$210$30,50132 claims
GSKBreo Ellipta$231$25,63360 claims
MerckJanuvia, Dulera$81$20,75327 claims
BayerKerendia$228$11,16111 claims
AbbVieSynthroid$516$3,11457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →